|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
645200070[A07151631]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml(2007.03.01)(ÇöÀç¾à°¡)
\10 ¿ø/1ml(2006.01.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
µÎµå·¯±â, °íÃÊ¿, ¾Ë·¹¸£±â ºñ¿°, °¡·Á¿ò, °á¸·¿°
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¡Û 2¼¼ ÀÌ»óÀÇ ¼Ò¾Æ
․ üÁß 40kg ¹Ì¸¸ : 1ÀÏ Ã¼Áß 5kg ´ç ÀÌ ¾à 2.5mL(¸ÞÄûŸÁøÀ¸·Î¼ 1.25mg)À» °æ±¸Åõ¿©ÇÑ´Ù.
․ üÁß 40kg ÀÌ»ó : 1ÀÏ ÀÌ ¾à 20mL(¸ÞÄûŸÁøÀ¸·Î¼ 10mg)À» °æ±¸Åõ¿©ÇÑ´Ù.
|
| ±Ý±â |
1) Æä³ëƼ¾ÆÁø°è ¾à¹° ¹× ±× À¯»çÈÇÕ¹°¿¡ °ú¹Î¹ÝÀÀ ȯÀÚ
2) ³ì³»ÀåȯÀÚ(Ç×Äݸ°ÀÛ¿ë¿¡ ÀÇÇÔ)
3) Àü¸³¼±ºñ´ë µî ÇϺοä·Î Æó»ö¼º ÁúȯȯÀÚ(Ç×Äݸ°ÀÛ¿ë¿¡ ÀÇÇÔ)
4) È¥¼ö»óÅ ȯÀÚ ¶Ç´Â ¹Ù¸£ºñÅ»°è ¾à¹°, ¸¶ÃëÁ¦ µî ÁßÃ߽Űæ¾ïÁ¦Á¦¸¦ ´ë·® Åõ¿©ÁßÀΠȯÀÚ
5) MAO¾ïÁ¦Á¦¸¦ Åõ¿©ÁßÀΠȯÀÚ
6) °£Áú ȯÀÚ
7) °£¿° ȯÀÚ
8) 2¼¼ ¹Ì¸¸ ¿µ¾Æ
9) ÀÌ ¾à¿¡ ¾Ë·¹¸£±â Áõ»óÀÇ º´·ÂÀÌ Àִ ȯÀÚ
10) ¼±ÃµÀû ±ä QT ÁõÈıº ȯÀÚ
11) QT°£°ÝÀÌ ±æ°Å³ª ÀüÇØÁú ºÒ±ÕÇü ȯÀÚ(ƯÈ÷, ÀúÄ®·ýÁõ ȯÀÚ)
|
| ½ÅÁßÅõ¿© |
1) ½ÅÀå¾Ö ȯÀÚ
2) °£Àå¾Ö ȯÀÚ
3) ÇùÂø¼º ¼Òȼº ±Ë¾ç ¶Ç´Â À¯¹®½ÊÀÌÁöÀå Æó»ö ȯÀÚ
4) ±Þ¼º ¾ËÄÚ¿Ã Áßµ¶ ȯÀÚ
5) À¯¹®½ÊÀÌÁöÀå ±Ë¾ç ȯÀÚ
6) Á¶Ç÷Àå¾Ö ȯÀÚ
7) õ½Ä, ±â°üÁö¿°, ±â°üÁöÈ®ÀåÁõ µî Çϱ⵵ Áúȯ ȯÀÚ
8) ¼ö¸é¹«È£ÈíÁõÀÇ º´·Â ȯÀÚ |
| ÀÌ»ó¹ÝÀÀ |
1) °ú¹Î¹ÝÀÀ : µå¹°°Ô ¹ßÁø, ±¤¹Î°¨¹ÝÀÀ, ÇǺιÝÀÀ(µ¶¼º, ¾Ë·¹¸£±â) µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Áõ»óÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù. º¹¿ë ÈÄ °ð¹Ù·Î µÎµå·¯±â, ºÎÁ¾, °¡½¿¾²¸² µî°ú µ¿½Ã¿¡ ¾È»öâ¹é, ¼öÁ·³Ã°¨, ½ÄÀº ¶¡, ¼û°¡»Õ µî ¼îÅ©(¾Æ³ªÇʶô½Ã½º)ÀÌ ³ªÅ¸³¯ °æ¿ì¿¡´Â Áï½Ã º¹¿ëÀ» ÁßÁöÇϰí ÀÇ»çÀÇ Áø·á¸¦ ¹Þ´Â´Ù.
2) °£ : µå¹°°Ô Àü½ÅÇÇ·Î, Ȳ´Þ, ALT, AST »ó½Â, ´ãÁó¿ïü°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰí ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
3) Ç÷¾× : µå¹°°Ô Á¶Ç÷Àå¾Ö·Î Ç÷¼ÒÆÇ °¨¼Ò°¡ ³ªÅ¸³ª ÄÚÃâÇ÷, ÀÕ¸öÃâÇ÷, û»ö¹ÝÁ¡ µîÀÇ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ»óÀÌ ÀÎÁ¤µÇ´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
4) Á¤½Å½Å°æ°è : ¶§¶§·Î Á¹À½, ±Ïۨ, ¾îÁö·³, µå¹°°Ô µÎÅë, Á¤½ÅÂø¶õ, ÈïºÐ, ºÒ¾ÈÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ¼Òȱâ°è : ¶§¶§·Î ±¸°¥, À§ºÎºÒÄè°¨, µå¹°°Ô ¼³»ç, À§Åë, ½Ä¿åºÎÁø, ±¸¿ª, ±¸Åä, º¯ºñ, º¹Åë µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
6) ¼øÈ¯±â°è : µå¹°°Ô ÈäºÎºÒÄè°¨, ½É°èÇ×Áø, ÀúÇ÷¾ÐÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
7) ºñ´¢±â°è : µå¹°°Ô ¹è´¢°ï¶õ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
8) ¾È°úÁúȯ : ¿ø±ÙÁ¶ÀýÀå¾Ö, »êµ¿
9) ½ÉÀå Áúȯ : Å丣»çµå µå Æ÷ÀÎÆ®(torsade de pointes)
10) ÇǺΠ¹× ÇÇÇÏÁ¶Á÷ : °¨±¤¼º ¹ÝÀÀ, È«¹Ý, ½ÀÁø, °¡·Á¿ò, ÀÚ¹ÝÁõ, µÎµå·¯±â, Ç÷°ü ½Å°æºÎÁ¾
11) ±âŸ : µå¹°°Ô ÀÎÈÄÅë, ¿ù°æÀÌ»ó, ¹Ì°¢ÀÌ»ó, ±¸³»¸¶ºñ°¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) ¹Ù¸£ºñÅ»°è ¾à¹°, ¸¶ÃëÁ¦, ¸¶¾à¼º ÁøÅëÁ¦ ¶Ç´Â Á¤½Å¾ÈÁ¤Á¦ µîÀÇ ÁßÃ߽Űæ¾ïÁ¦Á¦, Ç׿ì¿ï¾à, Ç÷¾Ð°ÇÏÁ¦ ¶Ç´Â ¾ÆÆ®·ÎÇɸð¾ç ÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾à¹°°ú º´¿ë ¶Ç´Â ¾ËÄÚ¿Ã ¼·Ãë¿¡ ÀÇÇØ »óÈ£ ÀÛ¿ëÀÌ Áõ°¡µÉ ¼ö ÀÖÀ¸¹Ç·Î °¨·®ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
2) ÁßÁõÀÇ ½É¹Ú Àå¾Ö´Â º´¿ë ¾à¹°ÀÇ ¼ö, Ç׺ÎÁ¤¸ÆÁ¦ÀÇ ¿©ºÎ¿¡ µû¶ó ¹ß»ýÇÒ ¼ö ÀÖÀ¸¹Ç·Î Å丣»çµå µå Æ÷ÀÎÆ®(torsade de pointes)¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Â ¾à¹°Àº º´¿ëÇÏÁö ¾Ê´Â´Ù.
3) ¿äÀú·ù, ³ì³»Àå, º¯ºñ, ÀÔ¸¶¸§ µîÀÇ ÀÌ»ó¹ÝÀÀ ¹ß»ýÀ» ÃËÁø½ÃŰ´Â ¾ÆÆ®·ÎÇÉ ¾à¹°Àº º´¿ëÇÏÁö ¾Ê´Â´Ù. |
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| ÈÇб¸Á¶ ¹× ¹°¼º |
[Mequitazine]
> [Mequitazine] CAS number/29216-28-2 ATC code/R06AD07 PubChem/4066 DrugBank/APRD00386 Formula/C20H22N2S Mol. mass/322.468 g/mol Bioavailability/ ? Metabolism/ ? Excretion/ ? Pregnancy cat./
? Legal status/ Routes/ ?
|
| Mechanism of Action |
Mequitazine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Mequitazine binds to the histamine H1 receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
|
| Pharmacology |
Mequitazine¿¡ ´ëÇÑ Pharmacology Á¤º¸ In allergic reactions an allergen interacts with and cross-links surface IgE antibodies on mast cells and basophils. Once the mast cell-antibody-antigen complex is formed, a complex series of events occurs that eventually leads to cell-degranulation and the release of histamine (and other chemical mediators) from the mast cell or basophil. Once released, histamine can react with local or widespread tissues through histamine receptors. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, and bronchoconstriction. Histamine also increases vascular permeability and potentiates pain. Mequitazine is a histamine H1 antagonist. It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
|
| Metabolism |
Mequitazine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6)
|
| Protein Binding |
Mequitazine¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Pharmacokinetics |
MequitazineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : °æ±¸ Åõ¿©½Ã ºÒ¿ÏÀüÇÏ°Ô Èí¼ö (70%)
- ÃÖ°íÇ÷Áß³óµµ µµ´Þ½Ã°£ : 5-7½Ã°£ (°øº¹ Åõ¿©½Ã)
- ´Ü¹é°áÇÕ : 90%, ´Ü¹é°áÇÕÀ²ÀÌ Å©±â ¶§¹®¿¡ °£ÁúȯÀ̳ª ±Þ¼º ÁúȯÀÌ ÀÖ´Â °æ¿ì ¾à¹°ÀÇ µ¿Å°¡ ´Þ¶óÁú ¼ö ÀÖÀ½
- ¹Ý°¨±â : ¾à 40 ½Ã°£
- ´ë»ç : »êÈ¿¡ ÀÇÇØ ´ë»ç (°£¿¡¼ ÁÖ·Î ´ë»çµÇ´Â °ÍÀ¸·Î ¿©°ÜÁü)
- ¼Ò½Ç : ´¢ (¹Ìº¯Èü´Â 1% ¹Ì¸¸), ´ëº¯(ÁÖ·Î ´ë»çü·Î¼ ¿ë·®ÀÇ 83%)À¸·Î ¹è¼³µÊ, Àå°£¸·¼øÈ¯À¸·Î ÀÎÇØ ´ëº¯À¸·Î ¹è¼³µÇ´Â ½Ã°£ÀÌ Áö¿¬µÊ
|
| Toxicity |
Mequitazine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Mequitazine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Mequitazine¿¡ ´ëÇÑ Description Á¤º¸ Mequitazine is a histamine H1 antagonist (antihistamine). It competes with histamine for the normal H1-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. It provides effective, temporary relief of sneezing, watery and itchy eyes, and runny nose due to hay fever and other upper respiratory allergies.
|
| Drug Category |
Mequitazine¿¡ ´ëÇÑ Drug_Category Á¤º¸ Bronchodilator AgentsHistamine H1 Antagonists
|
| Smiles String Canonical |
Mequitazine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ C1CN2CCC1C(C2)CN1C2=CC=CC=C2SC2=CC=CC=C12
|
| Smiles String Isomeric |
Mequitazine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C1C[N@@]2CC[C@H]1[C@H](C2)CN1C2=CC=CC=C2SC2=CC=CC=C12
|
| InChI Identifier |
Mequitazine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2
|
| Chemical IUPAC Name |
Mequitazine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 10-(1-azabicyclo[2.2.2]octan-8-ylmethyl)phenothiazine
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-05-25
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|